{
  "drug_name": "Patisiran (Onpattro)",
  "fda_approval_date": "2018-08-10",
  "indication": "Hereditary transthyretin-mediated (hATTR) amyloidosis",
  "target_gene": "TTR",
  "target_transcript": "NM_000371",
  "patent": "US10060921B2",
  "patent_url": "https://patents.google.com/patent/US10060921B2",
  
  "sequences": {
    "patisiran_ttr_guide": {
      "id": "patisiran_ttr_guide",
      "sequence": "AUGGAAUACUCUUGGUUAC",
      "target_gene": "TTR",
      "strand_role": "guide",
      "overhang": "dTdT",
      "chem_mods": [
        {
          "type": "2OMe",
          "positions": [1, 4, 6, 11, 13, 16, 19],
          "notes": "2'-O-methyl ribose modifications"
        }
      ],
      "provenance": {
        "source_type": "patent",
        "identifier": "US10060921B2",
        "url": "https://patents.google.com/patent/US10060921B2"
      },
      "confirmation_status": "confirmed",
      "notes": "FDA-approved guide strand sequence from Patisiran (Onpattro). First FDA-approved RNAi therapeutic (2018)."
    },
    "patisiran_ttr_passenger": {
      "id": "patisiran_ttr_passenger",
      "sequence": "GUAACCAAGAGUAUUCCAU",
      "target_gene": "TTR",
      "strand_role": "passenger",
      "overhang": "dTdT",
      "chem_mods": [
        {
          "type": "2OMe",
          "positions": [3, 8, 10, 15],
          "notes": "Limited modifications on passenger strand"
        }
      ],
      "provenance": {
        "source_type": "patent",
        "identifier": "US10060921B2",
        "url": "https://patents.google.com/patent/US10060921B2"
      },
      "confirmation_status": "confirmed",
      "notes": "Passenger strand complementary to guide. Designed to be preferentially degraded."
    }
  },
  
  "clinical_data": {
    "efficacy": "Significant reduction in serum TTR levels",
    "safety": "Generally well tolerated with manageable infusion-related reactions",
    "delivery": "Lipid nanoparticle (LNP) formulation",
    "dosing": "0.3 mg/kg every 3 weeks via IV infusion",
    "target_tissue": "Liver (hepatocytes)"
  },
  
  "modification_rationale": {
    "guide_pattern": "Strategic 2'-O-methyl modifications at positions 1,4,6,11,13,16,19 provide optimal balance of stability and RISC loading efficiency",
    "passenger_pattern": "Limited modifications on passenger strand reduce its activity and promote degradation",
    "overhang": "dTdT DNA overhangs provide nuclease resistance and are compatible with LNP delivery",
    "overall_strategy": "Pattern optimized through extensive medicinal chemistry to achieve therapeutic efficacy with acceptable safety profile"
  },
  
  "references": [
    {
      "type": "publication",
      "title": "An RNAi therapeutic targeting transthyretin in hereditary transthyretin amyloidosis",
      "journal": "New England Journal of Medicine",
      "year": 2018,
      "pubmed_id": "30145929",
      "doi": "10.1056/NEJMoa1716153"
    },
    {
      "type": "patent",
      "identifier": "US10060921B2",
      "title": "Methods and compositions for treating transthyretin (TTR) related ocular amyloidosis",
      "url": "https://patents.google.com/patent/US10060921B2"
    }
  ],
  
  "notes": [
    "First FDA-approved RNAi therapeutic - landmark achievement",
    "Modification pattern validated in clinical trials",
    "Demonstrates feasibility of siRNA therapeutics",
    "Pattern can serve as template for other liver-targeted siRNAs",
    "Requires specialized LNP delivery system for in vivo efficacy"
  ]
}
